U.S. starts enrollment in trial testing Siga's antiviral for monkeypox

Reuters2022-09-10

Sept 9 (Reuters) - The National Institutes of Health (NIH) said on Friday it had started enrolling monkeypox patients in a late-stage study testing Siga Technologies Inc's antiviral pill Tpoxx against the disease.

The oral and intravenous formulations of Tpoxx are approved by the U.S. Food and Drug Administration for the treatment of smallpox, but does not yet have clearance to treat monkeypox.

It is, however, currently accessible by clinicians for treating monkeypox under a compassionate use request.

The NIH aims to enroll more than 500 patients, including both adults and children, who will then be randomized to receive either Tpoxx or placebo pills for 14 days.

Investigators will evalutate if participants receiving Tpoxx heal more quickly compared to placebo, as well as provide critical data on the optimal dosing and safety of the drug in children and people who are pregnant.

The United States has recorded more than 21,000 confirmed cases of monkeypox, according to data from the Centers for Disease Control and Prevention.

(Reporting by Raghav Mahobe; Editing by Maju Samuel)

((Raghav.Mahobe@thomsonreuters.com;))

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2266870078?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2022-09-10 00:59","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2266870078","market":"us","top_or_hot":-1,"title":"U.S. starts enrollment in trial testing Siga's antiviral for monkeypox","media":"Reuters","content":"<html><body><p>Sept 9 (Reuters) - The National Institutes of Health (NIH) said on Friday it had started enrolling monkeypox patients in a late-stage study testing Siga Technologies Inc's    antiviral pill Tpoxx against the disease.</p><p>   The oral and intravenous formulations of Tpoxx are approved by the U.S. Food and Drug Administration for the treatment of smallpox, but does not yet have clearance to treat monkeypox.</p><p>   It is, however, currently accessible by clinicians for treating monkeypox under a compassionate use request.</p><p>   The NIH aims to enroll more than 500 patients, including both adults and children, who will then be randomized to receive either Tpoxx or placebo pills for 14 days.</p><p>   Investigators will evalutate if participants receiving Tpoxx heal more quickly compared to placebo, as well as provide critical data on the optimal dosing and safety of the drug in children and people who are pregnant.</p><p>   The United States has recorded more than 21,000 confirmed cases of monkeypox, according to data from the Centers for Disease Control and Prevention.</p><p> (Reporting by Raghav Mahobe; Editing by Maju Samuel)</p><p>((Raghav.Mahobe@thomsonreuters.com;))</p></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>U.S. starts enrollment in trial testing Siga's antiviral for monkeypox</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nU.S. starts enrollment in trial testing Siga's antiviral for monkeypox\n</h2>\n\n<h4 class=\"meta\">\n\n\n2022-09-10 00:59 GMT+8&nbsp;&nbsp;&nbsp;<a href=http://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1><strong>Reuters</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Sept 9 (Reuters) - The National Institutes of Health (NIH) said on Friday it had started enrolling monkeypox patients in a late-stage study testing Siga Technologies Inc's    antiviral pill Tpoxx ...</p>\n\n<a href=\"http://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4583","symbol_name":"猴痘概念","start_time":0,"source_url":"http://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","article_id":"2266870078","we_media_id":"1036604489","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2266870078","pubTimestamp":1662742778,"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1036604489","head_image":"https://static.tigerbbs.com/443ce19704621c837795676028cec868"},"summary":"Sept 9 (Reuters) - The National Institutes of Health (NIH) said on Friday it had started enrolling m","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4583":"猴痘概念","SIGA":"SIGA Technologies Inc","BK4007":"制药"},"translate_title":"美国开始注册SIgA猴痘抗病毒药物的试验","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"SIGA":0.9},"content_text":"Sept 9 (Reuters) - The National Institutes of Health (NIH) said on Friday it had started enrolling monkeypox patients in a late-stage study testing Siga Technologies Inc's    antiviral pill Tpoxx against the disease.   The oral and intravenous formulations of Tpoxx are approved by the U.S. Food and Drug Administration for the treatment of smallpox, but does not yet have clearance to treat monkeypox.   It is, however, currently accessible by clinicians for treating monkeypox under a compassionate use request.   The NIH aims to enroll more than 500 patients, including both adults and children, who will then be randomized to receive either Tpoxx or placebo pills for 14 days.   Investigators will evalutate if participants receiving Tpoxx heal more quickly compared to placebo, as well as provide critical data on the optimal dosing and safety of the drug in children and people who are pregnant.   The United States has recorded more than 21,000 confirmed cases of monkeypox, according to data from the Centers for Disease Control and Prevention. (Reporting by Raghav Mahobe; Editing by Maju Samuel)((Raghav.Mahobe@thomsonreuters.com;))","kind":null,"is_publish_news":null,"is_publish_highlight":null,"is_publish_live":null,"is_publish_wemedia":null,"editions":null,"symbols":[],"gpt_button":1},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.22.4","shortVersion":"4.22.4","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2266870078"}